Search results
Results from the WOW.Com Content Network
Lipinski's rule of five, also known as Pfizer's rule of five or simply the rule of five (RO5), is a rule of thumb to evaluate druglikeness or determine if a chemical compound with a certain pharmacological or biological activity has chemical properties and physical properties that would likely make it an orally active drug in humans.
A traditional method to evaluate druglikeness is to check compliance of Lipinski's rule of five, which covers the numbers of hydrophilic groups, molecular weight and hydrophobicity. Since the drug is transported in aqueous media like blood and intracellular fluid, it has to be sufficiently water-soluble in the absolute sense (i.e. must have a ...
Christopher A. Lipinski is a medicinal chemist who is working at Pfizer, Inc. [1] He is known for his "rule of five" , an algorithm that predicts drug compounds that are likely to have oral activity. [ 1 ]
It might be helpful for people new to Lipinski's rule to have a description of "Clog" on the page. It is an unusual and somewhat confusing notation. Could someone please add this information? 6.626X10^-34 16:45, 26 September 2024 (UTC)
Bill Lipinski (born 1937), Polish-American politician; Christopher A. Lipinski, originator of Lipinski's rule of five to evaluate druglikeness; Dan Lipinski (born 1966), Polish-American politician; Dariusz Lipiński (born 1955), Polish politician; Edward Lipiński (economist) (1888-1986), Polish economist; Jacek Lipiński (born 1966), Polish ...
The definitions of hydrogen bond donors and acceptors used to apply Lipinski's Rule of Five [6] are easily coded in SMARTS. Donors are defined as nitrogen or oxygen atoms that have at least one directly bonded hydrogen atom: [N,n,O;!H0] or [#7,#8;!H0] (aromatic oxygen cannot have a bonded hydrogen)
Lipinski won the gold medal at the 1998 Nagano Games at the age of 15, the youngest winner of an Olympic winter event. Weir competed at the 2006 and 2010 Winter Olympics.
Lipophilic efficiency [1] (LiPE), sometimes referred to as ligand-lipophilicity efficiency (LLE) is a parameter used in drug design and drug discovery to evaluate the quality of research compounds, linking potency and lipophilicity in an attempt to estimate druglikeness.